Reported resultsCompany-reported
What was reported
BOSTON, Mass – August 5, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the second quarter of 2026 that ended June 30, 2026. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
What the evidence supports
Ginkgo Bioworks published its results for the period in a press release furnished to the SEC (Form 8-K, Item 2.02).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $20 million | “•Second quarter 2026 Revenue of $20 million compared to $39 million in the comparable prior year period, a decrease of 48%.” Mentions: revenue |
| $39 million | “•Second quarter 2026 Revenue of $20 million compared to $39 million in the comparable prior year period, a decrease of 48%.” Mentions: revenue |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineGinkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of MarylandU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Press release lead paragraphBOSTON, Mass – August 5, 2026 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo”) today announced its results for the second quarter of 2026 that ended June 30, 2026. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Amount stated in press release•Second quarter 2026 Revenue of $20 million compared to $39 million in the comparable prior year period, a decrease of 48%.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Aug 5, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.